Anti-influenza virus agent for suppressing aggravation of influenza

An influenza virus and anti-influenza technology, applied in antiviral agents, medical preparations containing active ingredients, pharmaceutical formulations, etc., can solve problems such as microbial influenza that have not yet been shown, and achieve the effect of inhibiting seriousness

Pending Publication Date: 2021-02-09
THE KITASATO INST +2
View PDF7 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] However, it has not been shown whether these microbes suppress the severity of influenza

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-influenza virus agent for suppressing aggravation of influenza
  • Anti-influenza virus agent for suppressing aggravation of influenza
  • Anti-influenza virus agent for suppressing aggravation of influenza

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0061][Example 1] Preparation of OLB6378 concentrated powder

[0062]Bifidobacterium bifidum OLB6378 strain (accession number NITEBP-31) was anaerobic and cultured in a whey protein decomposition medium (a medium that uses enzymatically decomposed whey protein as the main nitrogen source). Obtain concentrated bacterial liquid. The concentrated bacterial solution was incubated at 80°C for more than 10 minutes, and then freeze-dried. The freeze-dried product obtained showed more than 2.5×1011Concentration of cells / g. The thus prepared freeze-dried product of the heat-treated OLB6378 strain was called OLB6378 concentrated powder, and the anti-influenza virus effect was tested as described later.

Embodiment 2

[0063][Example 2] Evaluation of the anti-influenza virus effect of OLB6378 concentrated powder

[0064]The anti-influenza virus effect of the OLB6378 concentrated powder prepared in Example 1 was evaluated in terms of "survival rate" after infection with influenza virus and "infectious viral value in respiratory organs (virus proliferation level)".

[0065]a) Survival rate

[0066]For BALB / c mice (female, 8 weeks old) (CLEA Japan, Inc.), water (water administration group) or OLB6378 concentrated powder was orally administered at a dose of 0.2 ml / person / day for 4 weeks 20% suspension (OLB6378 / Bifidobacterium administration group). At a time point 3 weeks after the start of oral administration, the anesthetic Somnopentyl(R)(5mg / kg body weight as the effective ingredient sodium pentobarbital) was administered intraperitoneally to anesthetize the mice, and the mouse domesticated influenza virus strain A / PR / 8 / 34 (H1N1) suspension was 20μl (2× LD50[Equivalent to twice the amount of lethal dose], 0...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention pertains to an anti-influenza virus agent that contains Bifidobacterium bifidum as an active ingredient.

Description

Technical field[0001]The present invention relates to an anti-influenza virus agent for suppressing the severity of influenza.Background technique[0002]Influenza is an infectious disease caused by infection with influenza virus. Influenza viruses are very infectious, and about 10 million people are infected in Japan each year. In addition, influenza is epidemic, so once it begins to spread, it spreads to many people in a short time. Elderly persons and chronically ill patients who have influenza have a high probability of becoming severely ill, and the risk of death due to complications such as pneumonia is also high.[0003]For the treatment of influenza, for example, anti-influenza drugs such as oseltamivir (trade name Tamiflu (registered trademark)) are generally used. Oseltamivir needs to be administered at an early stage within 48 hours after the onset of illness. On the other hand, if the detection period is too early, the virus may not be detected and the flu may not be diagnos...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A23L33/135A61K35/745A61P31/16
CPCA61K35/745A61P31/16A23L33/135
Inventor 永井隆之清原宽章神野慎治小堤大介
Owner THE KITASATO INST
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap